Advertisement

Tumor Biology

, Volume 33, Issue 3, pp 865–875 | Cite as

Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol

  • Dimitrios Korbakis
  • Andreas Scorilas
Research Article

Abstract

The BCL2 family of proteins includes apoptosis-related molecules involved in normal physiology, as well as cancer pathology. Members of our team have discovered and cloned the novel gene BCL2L12, which codes for a protein member of the BCL2 family. The BCL2L12 expression has been studied extensively in various types of cancer and its important clinical value has been underlined. The main objective of this study is the relative quantification of the mRNA expression of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric cancer cells, following treatment with anticancer drugs. Gastric adenocarcinoma cells AGS were treated with various concentrations of the chemical substances cisplatin, etoposide and taxol for three time periods. Cell viability was examined by using the MTT assay. Total RNA was extracted and reverse transcribed into cDNA. A highly sensitive, quantitative real-time PCR method was developed based on the SYBR Green chemistry, for the proper mRNA quantification. GAPDH was used as a housekeeping gene. Relative quantification analysis was performed by using the comparative CT method (\( 2^{−{\text{DDC}}_{\text{T}}} \)). Treatment of AGS cells with 10 μM cisplatin, 0.5 μM etoposide and 10 nM taxol affected the BCL2, BAX and BCL2L12 mRNA levels, compared to the untreated cells. Cisplatin and etoposide induced a major down-regulation in the BCL2 mRNA levels after 72 h of treatment, while the BAX mRNA levels were slightly up-regulated. Moreover, taxol had an up-regulating effect on both BCL2 and BAX transcript levels after 48 h of incubation. Chemotherapy had a much smaller effect on the BCL2L12 expression levels, eventually characterised by a small down-regulation.

Keywords

AGS gastric adenocarcinoma cell line Apoptosis BCL2 family BCL2L12 Real-Time PCR Anticancer drugs 

Abbreviations

BCL2

B-cell CLL/lymphoma 2

BCL2L12

BCL2 like gene 12

BH domain

BCL2 homology domains

CA 19-9

Carbohydrate antigen 19-9

CA 72-4

Cancer antigen 72-4

CEA

Carcinoembryonic antigen

CLL

Chronic lymphocytic leukaemia

DFS

Disease-free survival

H. pylori

Helicobacter pylori

IRF3

Interferon regulatory factor 3 gene

PRMT1/HRMT1L2

Protein arginine methyltransferase 1 gene

SSCP

Single-strand conformation polymorphism

Notes

Acknowledgements

The project was supported by a PENED grant co-funded by the European Union–European Social Funds (75% from the European Union), National Resources (25% from governmental funds)–Ministry of Development–General Secretariat for Research & Technology of Greece and ELPEN A.E. through EPAN.M.8.3—3rd Community Support Programme.

Conflicts of interest

None

References

  1. 1.
    Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239–57.PubMedCrossRefGoogle Scholar
  2. 2.
    Thomadaki H, Scorilas A. Bcl2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci. 2006;43:1–67.PubMedCrossRefGoogle Scholar
  3. 3.
    Petros AM, Olejniczak ET, Fesik SW. Structural biology of the bcl-2 family of proteins. Biochim Biophys Acta. 2004;1644:83–94.PubMedCrossRefGoogle Scholar
  4. 4.
    Adams JM, Cory S. The bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Hanada M, Aime-Sempe C, Sato T, Reed JC. Structure–function analysis of bcl-2 protein. Identification of conserved domains important for homodimerization with bcl-2 and heterodimerization with bax. J Biol Chem. 1995;270:11962–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Zivny J, Klener Jr P. Pytlik R, Andera L: The role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies. Curr Pharm Des. 2010;16:11–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Kirkin V, Joos S, Zornig M. The role of bcl-2 family members in tumorigenesis. Biochim Biophys Acta. 2004;1644:229–49.PubMedCrossRefGoogle Scholar
  8. 8.
    Apte SS, Mattei MG, Olsen BR. Mapping of the human bax gene to chromosome 19q13.3-q13.4 and isolation of a novel alternatively spliced transcript, bax delta. Genomics. 1995;26:592–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell. 1994;79:189–92.PubMedCrossRefGoogle Scholar
  10. 10.
    Scorilas A, Kyriakopoulou L, Yousef GM, Ashworth LK, Kwamie A, Diamandis EP. Molecular cloning, physical mapping, and expression analysis of a novel gene, bcl2l12, encoding a proline-rich protein with a highly conserved bh2 domain of the bcl-2 family. Genomics. 2001;72:217–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Fenogilo-Preiser C, Carneiro F, Correa P. Gastric carcinoma. In: Hamilton S, Aaltonin L, editors. Pathology and genetics tumors of the digestive system, vol 1. Lyon: Lyon Press; 2000.Google Scholar
  12. 12.
    Partridge M, Gaballah K, Huang X. Molecular markers for diagnosis and prognosis. Cancer Metastasis Rev. 2005;24:71–85.PubMedCrossRefGoogle Scholar
  13. 13.
    Schwartz GK. Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations. Semin Oncol. 1996;23:316–24.PubMedGoogle Scholar
  14. 14.
    Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol. 2009;71:127–64.PubMedCrossRefGoogle Scholar
  15. 15.
    Ebert MP, Rocken C. Molecular screening of gastric cancer by proteome analysis. Eur J Gastroenterol Hepatol. 2006;18:847–53.PubMedCrossRefGoogle Scholar
  16. 16.
    Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature. 1990;348:331–3.PubMedCrossRefGoogle Scholar
  17. 17.
    Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309–12.PubMedCrossRefGoogle Scholar
  18. 18.
    Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63.PubMedCrossRefGoogle Scholar
  19. 19.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−delta delta c(t)) method. Methods. 2001;25:402–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Katsumata M, Siegel RM, Louie DC, Miyashita T, Tsujimoto Y, Nowell PC, et al. Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc Natl Acad Sci USA. 1992;89:11376–80.PubMedCrossRefGoogle Scholar
  21. 21.
    McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP, et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 1989;57:79–88.PubMedCrossRefGoogle Scholar
  22. 22.
    Bairey O, Zimra Y, Shaklai M, Okon E, Rabizadeh E. Bcl-2, Bcl-x, Bax, and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas. Clin Cancer Res. 1999;5:2860–6.PubMedGoogle Scholar
  23. 23.
    Binder C, Marx D, Overhoff R, Binder L, Schauer A, Hiddemann W. Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Ann Oncol. 1995;6:1005–10.PubMedGoogle Scholar
  24. 24.
    Campana D, Coustan-Smith E, Manabe A, Buschle M, Raimondi SC, Behm FG, et al. Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein. Blood. 1993;81:1025–31.PubMedGoogle Scholar
  25. 25.
    Campos L, Sabido O, Sebban C, Charrin C, Bertheas MF, Fiere D, et al. Expression of bcl-2 proto-oncogene in adult acute lymphoblastic leukemia. Leukemia. 1996;10:434–8.PubMedGoogle Scholar
  26. 26.
    Flohil CC, Janssen PA, Bosman FT. Expression of bcl-2 protein in hyperplastic polyps, adenomas, and carcinomas of the colon. J Pathol. 1996;178:393–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer. 1995;71:1003–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol. 1998;9:159–65.PubMedCrossRefGoogle Scholar
  29. 29.
    Laudanski J, Chyczewski L, Niklinska WE, Kretowska M, Furman M, Sawicki B, et al. Expression of bcl-2 protein in non-small cell lung cancer: correlation with clinicopathology and patient survival. Neoplasma. 1999;46:25–30.PubMedGoogle Scholar
  30. 30.
    Ramsay JA, From L, Kahn HJ. Bcl-2 protein expression in melanocytic neoplasms of the skin. Mod Pathol. 1995;8:150–4.PubMedGoogle Scholar
  31. 31.
    Schorr K, Li M, Krajewski S, Reed JC, Furth PA. Bcl-2 gene family and related proteins in mammary gland involution and breast cancer. J Mammary Gland Biol Neoplasia. 1999;4:153–64.PubMedCrossRefGoogle Scholar
  32. 32.
    Tsuji M, Murakami Y, Kanayama H, Sano T, Kagawa S. Immunohistochemical analysis of Ki-67 antigen and Bcl-2 protein expression in prostate cancer: effect of neoadjuvant hormonal therapy. Br J Urol. 1998;81:116–21.PubMedCrossRefGoogle Scholar
  33. 33.
    Konturek PC, Konturek SJ, Sulekova Z, Meixner H, Bielanski W, Starzynska T, et al. Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis related proteins Bax and Bcl-2, and gastrin in human gastric cancer. Aliment Pharmacol Ther. 2001;15:989–99.PubMedCrossRefGoogle Scholar
  34. 34.
    Krajewska M, Fenoglio-Preiser CM, Krajewski S, Song K, Macdonald JS, Stemmerman G, et al. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol. 1996;149:1449–57.PubMedGoogle Scholar
  35. 35.
    Lauwers GY, Scott GV, Karpeh MS. Immunohistochemical evaluation of bcl-2 protein expression in gastric adenocarcinomas. Cancer. 1995;75:2209–13.PubMedCrossRefGoogle Scholar
  36. 36.
    Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett. 2008;266:99–115.PubMedCrossRefGoogle Scholar
  37. 37.
    Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer. 2003;97:545–53.PubMedCrossRefGoogle Scholar
  38. 38.
    Richardson A, Kaye SB. Pharmacological inhibition of the bcl-2 family of apoptosis regulators as cancer therapy. Curr Mol Pharmacol. 2008;1:244–54.PubMedCrossRefGoogle Scholar
  39. 39.
    Thomadaki H, Scorilas A. Molecular profile of the bcl2 family of the apoptosis related genes in breast cancer cells after treatment with cytotoxic/cytostatic drugs. Connect Tissue Res. 2008;49:261–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Floros KV, Talieri M, Scorilas A. Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Biol Chem. 2006;387:1629–33.PubMedCrossRefGoogle Scholar
  41. 41.
    Floros KV, Thomadaki H, Katsaros N, Talieri M, Scorilas A. mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004;385:1099–103.PubMedCrossRefGoogle Scholar
  42. 42.
    Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2:594–604.PubMedCrossRefGoogle Scholar
  43. 43.
    Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303:1010–4.PubMedCrossRefGoogle Scholar
  44. 44.
    Kaneuchi M, Yamashita T, Shindoh M, Segawa K, Takahashi S, Furuta I, et al. Induction of apoptosis by the p53-273l (Arg → Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax. Mol Carcinog. 1999;26:44–52.PubMedCrossRefGoogle Scholar
  45. 45.
    Salah-eldin A, Inoue S, Tsuda M, Matsuura A. Abnormal intracellular localization of Bax with a normal membrane anchor domain in human lung cancer cell lines. Jpn J Cancer Res. 2000;91:1269–77.PubMedCrossRefGoogle Scholar
  46. 46.
    Sturm I, Papadopoulos S, Hillebrand T, Benter T, Luck HJ, Wolff G, et al. Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 gene. Int J Cancer. 2000;87:517–21.PubMedCrossRefGoogle Scholar
  47. 47.
    Gil J, Yamamoto H, Zapata JM, Reed JC, Perucho M. Impairment of the proapoptotic activity of Bax by missense mutations found in gastrointestinal cancers. Cancer Res. 1999;59:2034–7.PubMedGoogle Scholar
  48. 48.
    Komatsu K, Suzuki S, Shimosegawa T, Miyazaki JI, Toyota T. Cre-loxP-mediated bax gene activation reduces growth rate and increases sensitivity to chemotherapeutic agents in human gastric cancer cells. Cancer Gene Ther. 2000;7:885–92.PubMedCrossRefGoogle Scholar
  49. 49.
    Floros KV, Thomadaki H, Florou D, Talieri M, Scorilas A. Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide. Ann N Y Acad Sci. 2006;1090:89–97.PubMedCrossRefGoogle Scholar
  50. 50.
    Stegh AH, Chin L, Louis DN, DePinho RA. What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2l12 as a multifunctional cell death regulator. Cell Cycle. 2008;7:2833–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Stegh AH, Kesari S, Mahoney JE, Jenq HT, Forloney KL, Protopopov A, et al. Bcl2l12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA. 2008;105:10703–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Stegh AH, Kim H, Bachoo RM, Forloney KL, Zhang J, Schulze H, et al. Bcl2l12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev. 2007;21:98–111.PubMedCrossRefGoogle Scholar
  53. 53.
    Stegh AH, Brennan C, Mahoney JA, Forloney KL, Jenq HT, Luciano JP, et al. Glioma oncoprotein bcl2l12 inhibits the p53 tumor suppressor. Genes Dev. 2010;24:2194–204.PubMedCrossRefGoogle Scholar
  54. 54.
    Nakajima A, Nishimura K, Nakaima Y, Oh T, Noguchi S, Taniguchi T, et al. Cell type-dependent proapoptotic role of bcl2l12 revealed by a mutation concomitant with the disruption of the juxtaposed irf3 gene. Proc Natl Acad Sci USA. 2009;106:12448–52.PubMedCrossRefGoogle Scholar
  55. 55.
    Hong Y, Yang J, Wu W, Wang W, Kong X, Wang Y, et al. Knockdown of BCL2L12 leads to cisplatin resistance in MDA-MB-231 breast cancer cells. Biochim Biophys Acta. 2008;1782:649–57.PubMedGoogle Scholar
  56. 56.
    Hong Y, Yang J, Chi Y, Wang W, Wu W, Yun X, et al. BCL2L12A localizes to the cell nucleus and induces growth inhibition through G2/M arrest in CHO cells. Mol Cell Biochem. 2010;333:323–30.PubMedCrossRefGoogle Scholar
  57. 57.
    Talieri M, Diamandis EP, Katsaros N, Gourgiotis D, Scorilas A. Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors. Thromb Haemost. 2003;89:1081–8.PubMedGoogle Scholar
  58. 58.
    Thomadaki H, Talieri M, Scorilas A. Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Lett. 2007;247:48–55.PubMedCrossRefGoogle Scholar
  59. 59.
    Mathioudaki K, Scorilas A, Papadokostopoulou A, Xynopoulos D, Arnogianaki N, Agnanti N, et al. Expression analysis of BCL2L12, a new member of apoptosis-related genes, in colon cancer. Biol Chem. 2004;385:779–83.PubMedCrossRefGoogle Scholar
  60. 60.
    Kontos CK, Papadopoulos IN, Scorilas A. Quantitative expression analysis and prognostic significance of the novel apoptosis-related gene BCL2L12 in colon cancer. Biol Chem. 2008;389:1467–75.PubMedCrossRefGoogle Scholar
  61. 61.
    Papageorgiou SG, Kontos CK, Pappa V, Thomadaki H, Kontsioti F, Dervenoulas J, et al. The novel member of the BCL2 gene family, BCL2L12, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker. Oncologist. 2011;16:1280–91.PubMedCrossRefGoogle Scholar
  62. 62.
    Fendri A, Kontos CK, Khabir A, Mokdad-Gargouri R, Scorilas A. BCL2L12 is a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma. Mol Med. 2011;17:163–71.PubMedCrossRefGoogle Scholar
  63. 63.
    Florou D, Papadopoulos IN, Scorilas A. Molecular analysis and prognostic impact of the novel apoptotic gene BCL2L12 in gastric cancer. Biochem Biophys Res Commun. 2010;391:214–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Floros KV, Thomadaki H, Lallas G, Katsaros N, Talieri M, Scorilas A. Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12. Ann N Y Acad Sci. 2003;1010:153–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Thomadaki H, Floros KV, Scorilas A. Molecular response of HL-60 cells to mitotic inhibitors vincristine and taxol visualized with apoptosis-related gene expressions, including the new member BCL2L12. Ann N Y Acad Sci. 2009;1171:276–83.PubMedCrossRefGoogle Scholar
  66. 66.
    Thomadaki H, Scorilas A. Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci. 2007;1095:35–44.PubMedCrossRefGoogle Scholar
  67. 67.
    Thomadaki H, Talieri M, Scorilas A. Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. Biol Chem. 2006;387:1081–6.PubMedCrossRefGoogle Scholar
  68. 68.
    Thomadaki H, Scorilas A. Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol. Biol Chem. 2008;389:1427–34.PubMedCrossRefGoogle Scholar
  69. 69.
    Zhuo Z, Zhang L, Mu Q, Lou Y, Gong Z, Shi Y, et al. The effect of combination treatment with docosahexaenoic acid and 5-fluorouracil on the mRNA expression of apoptosis-related genes, including the novel gene BCL2L12, in gastric cancer cells. In Vitro Cell Dev Biol Anim. 2009;45:69–74.PubMedCrossRefGoogle Scholar
  70. 70.
    Korbakis D, Scorilas A. Treatment of gastric cancer cells with 5-fluorouracil/leucovorin and irinotecan induces distinct alterations in the mRNA expression of the apoptosis-related genes, including the novel gene BCL2L12. Tumour Biol. 2009;30:100–7.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  1. 1.Department of Biochemistry and Molecular Biology, Faculty of BiologyNational and Kapodistrian University of AthensAthensGreece

Personalised recommendations